Y-mAbs Therapeutics
Manufacturing · New Jersey, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
202 Carnegie Ctr Ste 301, Princeton, New...Phone Number
(646) 885-8505Website
www.ymabs.comRevenue
$85.4 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Y-mAbs Therapeutics
Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The Company has a broad and advanced product pipeline, including one FDA approved product, DANYELZA® (naxitamab-gqgk), which targets tumors that express GD2, and one pivotal-stage product candidate, omburtamab, which targets tumors that express B7-H3.Explore more
Y-mAbs Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Y-mAbs Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Y-mAbs Therapeutics is spiking on competitors!
Product Launch: Get notified when Y-mAbs Therapeutics launches new products
Click to see if Y-mAbs Therapeutics had a recent Job posting/layoffs
Check if Y-mAbs Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Y-mAbs Therapeutics recently announced quarterly report
Y-mAbs Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Y-mAbs Therapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Y-mAbs Therapeutics
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Y-mAbs Therapeutics
Compare insights from companies similar to Y-mAbs Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Y-mAbs Therapeutics
$85.4M
51-200
Private
$434.2M
2015
RG
Robert GunningVice President, Finance & Corporate Controller
$105M
201-500
Public
$237.2M
1997
CE
Celia EckertSenior Vice President, General Counsel & Corporate Secretary
Company Profile Activity
Activity Insights
Y-mAbs Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Y-mAbs Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Y-mAbs Therapeutics.
Y-mAbs Therapeutics financials insights
Gather financial insights about Y-mAbs Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Share Placement
$80M
2018
Stock Offering
$110.4M
2019
Stock Offering
$143.8M
2021
Stock Offering
$100M
Y-mAbs Therapeutics Tech Stack
A closer look at the technologies used by Y-mAbs Therapeutics
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Left Company
Executive Move
Executive Moves, Left Company
Person-Based
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Y-mAbs Therapeutics
Sign Up For FreeTo access detailed company insights
Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The Company has a broad and advanced product pipeline, including one FDA approved product, DANYELZA® (naxitamab-gqgk), which targets tumors that express GD2, and one pivot... Read More
